|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.69(B) |
Last
Volume: |
1,031,697 |
Avg
Vol: |
1,398,626 |
52
Week Range: |
$76.22 - $100.3 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
92,341 |
116,105 |
269,465 |
610,463 |
Total Sell Value |
$8,237,699 |
$10,489,308 |
$24,880,826 |
$57,517,351 |
Total People Sold |
3 |
4 |
5 |
8 |
Total Sell Transactions |
9 |
11 |
22 |
59 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-14 |
4 |
S |
$70.17 |
$1,052,492 |
I/I |
(15,000) |
20,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-14 |
4 |
OE |
$12.99 |
$194,850 |
I/I |
15,000 |
35,609 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-05-14 |
4 |
S |
$70.33 |
$348,045 |
D/D |
(4,947) |
6,660 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-05-14 |
4 |
OE |
$21.51 |
$75,285 |
D/D |
3,500 |
10,160 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-05-14 |
4 |
AS |
$70.00 |
$1,400,000 |
D/D |
(20,000) |
50,262 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-05-14 |
4 |
OE |
$21.51 |
$430,200 |
D/D |
20,000 |
70,262 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-05-14 |
4 |
S |
$70.34 |
$1,406,800 |
D/D |
(20,000) |
41,708 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-05-14 |
4 |
OE |
$21.51 |
$430,200 |
D/D |
20,000 |
61,708 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-14 |
4 |
S |
$70.74 |
$1,773,551 |
I/I |
(25,000) |
20,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-14 |
4 |
OE |
$12.99 |
$324,750 |
I/I |
25,000 |
45,609 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-05-13 |
4 |
AS |
$69.26 |
$86,431 |
D/D |
(1,248) |
7,270 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-13 |
4 |
AS |
$69.11 |
$552,896 |
I/I |
(8,000) |
20,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-13 |
4 |
OE |
$12.99 |
$103,920 |
I/I |
8,000 |
28,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-13 |
4 |
AS |
$68.12 |
$479,720 |
D/D |
(7,000) |
88,101 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
7,064 |
20,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,064 |
90,101 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-05-13 |
4 |
S |
$69.29 |
$179,452 |
D/D |
(2,590) |
41,708 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-12 |
4/A |
D |
$67.68 |
$591,659 |
D/D |
(8,742) |
102,165 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2013-05-12 |
4 |
D |
$67.68 |
$152,821 |
D/D |
(2,258) |
20,277 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-05-12 |
4 |
D |
$67.68 |
$55,295 |
D/D |
(817) |
8,107 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2013-05-12 |
4 |
D |
$67.68 |
$203,108 |
D/D |
(3,001) |
39,373 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-05-12 |
4 |
D |
$67.68 |
$50,895 |
D/D |
(752) |
8,518 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-12 |
4 |
D |
$67.68 |
$600,525 |
D/D |
(8,873) |
102,165 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-05-12 |
4 |
D |
$67.68 |
$74,177 |
D/D |
(1,096) |
44,298 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-10 |
4 |
AS |
$67.48 |
$53,985 |
D/D |
(800) |
111,038 |
|
- |
|
1303 Records found
|
|
Page 10 of 53 |
|
|